Roche’s Venclexta data from ASH position drug as new AML standard of care, doctor says

The drug, combined with Celgene’s Vidaza, Otsuka’s Dacogen or low-dose cytarabine, showed strong response rates in elderly and unfit AML patients, historically a hard-to-treat population.

Article Source: Roche’s Venclexta data from ASH position drug as new AML standard of care, doctor says.